Fundraising Fox
Omniose
St. Louis, US · 23 employees on LinkedIn · 1 known investors
Find your way into Omniose
Sign up to see every warm intro you have to Omniose
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Omniose team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.
Founders & leadership
DH
Dr. HardingPrimary Founder
MF
Mario FeldmanFounder, Scientific Founder
VP
Viliam Pavliak
Board
DS
Dr. Szymanski
DP
Dr. Projan
DC
Dr. Cooke
Investors · 1
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Noveome BiotherapeuticsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
Companies working in the same space as Omniose.
In the news
Frequently asked questions
- What does Omniose do?
- Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.
- Who founded Omniose?
- Omniose was founded by Dr. Harding, Mario Feldman.
- Who are Omniose's investors?
- Omniose's investors include BioGenerator Ventures.
- Where is Omniose headquartered?
- Omniose is headquartered in St. Louis, US.